CLINICAL TRIAL

Neuroplasticity-based Computerized Cognitive Remediation for Cognitive Decline

Waitlist Available · 18+ · All Sexes · Nashville, TN

Computerized Memory Enhancing Treatment in MCI

See full description

About the trial for Cognitive Decline

Eligible Conditions
Cognitive Dysfunction · Mild Cognitive Impairment (MCI)

Treatment Groups

This trial involves 2 different treatments. Neuroplasticity-based Computerized Cognitive Remediation is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Neuroplasticity-based Computerized Cognitive Remediation
BEHAVIORAL
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

About The Treatment

Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Neuroplasticity-based Computerized Cognitive Remediation
2020
N/A
~30

Eligibility

This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
You have a subjective memory concern as reported by participant, study partner or clinician. show original
Clinical Dementia Rating16 Global score of 0.5
Mini-Mental State Exam score between 22-30 (inclusive)
General cognition and functional performance sufficiently preserved such that a diagnosis of Alzheimer's disease dementia cannot be made by the site clinician at the time of the screening visit
Geriatric Depression Scale score of less than or equal to 14
Study Partner is available who has frequent contact with the participant (e.g. an average of 10 hours per week or more), and can accompany the participant to most visits to answer questions about the participant
Good general health with no additional diseases/disorders expected to interfere with the study
You have a body mass index (BMI) of between 18 and 35. show original
You have adequate visual and auditory acuity to allow neuropsychological testing. show original
You are not pregnant, lactating, or of childbearing potential. show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 2 years
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 2 years.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Neuroplasticity-based Computerized Cognitive Remediation will improve 3 primary outcomes in patients with Cognitive Decline. Measurement will happen over the course of Through study completion, an average of 6 weeks..

Evaluate visit duration throughout nCCR treatment
THROUGH STUDY COMPLETION, AN AVERAGE OF 6 WEEKS.
Assess the duration of visits during nCCR treatment
THROUGH STUDY COMPLETION, AN AVERAGE OF 6 WEEKS.
Evaluate visit frequency throughout nCCR treatment
THROUGH STUDY COMPLETION, AN AVERAGE OF 6 WEEKS.
Assess the frequency of visits during nCCR treatment
THROUGH STUDY COMPLETION, AN AVERAGE OF 6 WEEKS.
Evaluate completion rates of nCCR
2 YEARS
Assess the percentage of enrolled participants who completed of the 40-hour nCCR treatment.
2 YEARS

Who is running the study

Principal Investigator
A. C. C.
Prof. Alexander Christian Conley, Research Assistant Professor
Vanderbilt University Medical Center

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the signs of cognitive decline?

Cognitive impairments include decreased alertness, lethargy, slowed responses, reduced speech rate and difficulty with attention. It can manifest in many ways and may cause significant difficulty with day-to-day functions. These deficits are often experienced as'slow' or'sluggish'.

Anonymous Patient Answer

How many people get cognitive decline a year in the United States?

As a whole, the age-specific incidence of cognitive decline appears relatively low in the U.S. population. However, there is a substantial proportion of people who may experience significant cognitive decline each year. The incidence of cognitive decline and the magnitude of cognitive decline appear to vary with age and race, but not with sex.

Anonymous Patient Answer

What are common treatments for cognitive decline?

There is the current research to support the use of cognitive rehabilitation therapy in the elderly population. However, no randomized controlled trials have been published that support its superiority over the regular care.

Anonymous Patient Answer

What causes cognitive decline?

Results from a recent clinical trial did not find one set of common factors that could explain why older adults experience cognitive impairment and the risk of developing Alzheimer's disease. The only factor that had associations with both was self-reported sleep deficit, which does not tell us what exactly is responsible for this phenomenon. Future work looks to identify those risk factors that explain why one person develops Alzheimer's, and that help us discover ways in which risk can be reduced.

Anonymous Patient Answer

What is cognitive decline?

Cognitive decline has become a widely occurring phenomenon among older adults in many parts of the world. The study of the complex biobehavioral processes involved in cognitive decline may lead to a greater understanding of what constitutes appropriate intervention strategies and to novel therapies which may provide protection against aging-related dysfunction of cognitive ability.

Anonymous Patient Answer

Can cognitive decline be cured?

Cognitive decline is a common phenomenon, and most people do not exhibit any deficits in IQ, at least up to age 76 and maybe even the 80s. However, cognitive decline can be slowed and reduced and its symptoms can be alleviated over the course of a few weeks, with more extensive and longer-term treatment.

Anonymous Patient Answer

What does neuroplasticity-based computerized cognitive remediation usually treat?

The present study demonstrates that neuroplasticity-based cognitive remediation can reduce some executive functions in healthy adults. Recent findings support the hypothesis that neuroplasticity-based computerized cognitive remediation can decrease some executive functions in older adults.

Anonymous Patient Answer

Have there been any new discoveries for treating cognitive decline?

Clinical trials have been performed to identify drugs or supplements that may slow the rate of cognitive decline for patients with mild cognitive impairment and may prevent the development of dementia. A number of promising candidates for treating or preventing cognitive decline include [Cilazapril, Memantine, and Prazosin]. A review of the evidence of medicines and supplements is in progress to provide the community and healthcare providers with the most evidence-based information for treating cognitive decline.

Anonymous Patient Answer

Have there been other clinical trials involving neuroplasticity-based computerized cognitive remediation?

Results from a recent clinical trial of this study support the possibility that neuroplasticity-based computerized cognitive remediation may offer a promising and inexpensive intervention to promote functional recovery in patients at risk of developing cognitive decline.

Anonymous Patient Answer

What is the latest research for cognitive decline?

[A recent meta-analysis of six separate studies on cognitive decline in adults aged 40-80 years from 1998 to 2009 confirms that cognition in later life, as measured via neuropsychological testing, is associated with most causes of mortality, including cardiovascular disease and death from non-cancer diseases (P=0.02-0.03]. Further research is needed to examine the role of early life health and lifestyles (physical activity, obesity, etc.

Anonymous Patient Answer

Is neuroplasticity-based computerized cognitive remediation typically used in combination with any other treatments?

Despite the lack of evidence-based studies, computerized CR-based interventions may be a promising part of an integrated treatment for cognitive impairment in people with IHD. Further studies are needed to determine the most appropriate frequency, dosing and rehabilitation strategy for people with IHD.

Anonymous Patient Answer

What are the latest developments in neuroplasticity-based computerized cognitive remediation for therapeutic use?

The use of computer-based cognitive remediation programs showed promise as a treatment option for improving performance on the neuropsychological tests analyzed herein. Recent findings of this preliminary study suggest that further study to clarify the clinical usefulness of such computer-based brain training protocols is warranted.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Cognitive Decline by sharing your contact details with the study coordinator.